factor viii inhibitor bypassing activity

Poland

Drugs containing this active substance

  • FEIBA NF

    The medicinal product is used for the treatment and prevention of bleeding in patients with haemophilia A or B who have a factor VIII or IX inhibitor. It may also be used in individuals without haemophilia but with acquired inhibitors of factors VIII, IX, and XI, and to assist in the complete elimination of factor VIII inhibitors during long-term treatment.

    Form: solution for injection, powder and solvent for preparation of

    Active substance Dosage
    human plasma protein 20-60 mg/1 mL
    factor viii inhibitor bypassing activity 50 units/1 mL

    ATC: B02BD03

    Manufacturer: Takeda Manufacturing Austria AG